We came across a bullish thesis on BioNTech SE on Lux Opes Research’s Substack. In this article, we will summarize the bulls’ thesis on BNTX. BioNTech SE’s share was trading at $118.00 as of January 26th. BNTX’s trailing and forward P/E were 166.87 and 7.04 respectively according to Yahoo Finance.
Pressmaster/Shutterstock.com
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies to treat cancer and infectious diseases in Germany. BNTX is entering 2026...
